HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme
Help Login Register
Market News Stocks News ETF News Crypto News

Esperion Therapeutics, Inc.

Contributing Author

Recent Articles by Esperion Therapeutics, Inc.

6 hours
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040 ESPR +8.08% GlobeNewswire
May-20
Esperion to Participate in Upcoming June Investor Conferences ESPR GlobeNewswire
May-12
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040 ESPR GlobeNewswire
May-09
Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference ESPR GlobeNewswire
May-08
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ESPR GlobeNewswire
May-08
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Canada ESPR GlobeNewswire
May-06
Esperion Reports First Quarter 2025 Financial Results ESPR GlobeNewswire
Affiliate • Advertise • Theme Settings • Contact • Help • Privacy • Do Not Sell My Data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.

Learn more about FINVIZ*Elite